GV has contributed to a $92m series B for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.

Tenaya Therapeutics, a US-based developer of treatments for heart disease based on research at Gladstone Institutes and University of Texas Southwestern Medical Center, yesterday raised $92m in a series B round led by Casdin Capital.
GV, an early-stage corporate venturing subsidiary of technology conglomerate Alphabet, also took part in the round, as did Column Group and a range of undisclosed new and existing shareholders.
Founded in 2016, Tenaya is working on drugs that address the underlying causes of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in